-
A Phase 1 Dose-escalation and Expansion Study of the PD-1 x ILT4 Bispecific Antibody CDX-585 in Patients with Advanced Malignancies
This is a study to test a new medicine called CDX-585 on patients with advanced or spreading solid tumors that have not improved with current ...
-
A Phase 1 Open-Label Multicenter Study to Assess Safety Tolerability PK and Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors
You can participate in this study if you are diagnosed with any of the advanced solid tumors found in any of the organ systems. The ... -
A PHASE 1 STUDY OF TJ033721 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS.
You can participate in this study if you are diagnosed with advanced solid tumors. The purpose of this study is to test the safety of ... -
A Phase 1/1b Open-label Multicenter Study to Investigate the Safety Tolerability Pharmacokinetics Pharmacodynamics and Anti-tumor Activity of KIN-3248 in Participants with Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations
This study is designed for patients who have Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations. This study is evaluating the safety, tolerability, pharmacokinetics ... -
An Open-Label Multicenter Phase 1a Study of AN2025 and AN0025 in Double Combination with Atezolizumab and in Triple Combination with Atezolizumab in Patients with Advanced Solid Tumors.
You can participate in this study if you are diagnosed with advanced solid tumors. The purpose of this study is to assess the Safety, Tolerability ... -
A Phase 1/1b Dose Escalation/Expansion Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors
This study is designed for patients diagnosed with Advanced or Metastatic Solid Tumors.
For Part 1A, this study will assess the safety and tolerability at ...
-
An Open Label First in Human (FIH) Phase 1 Trial of LVGN6051 as Single Agent and in Combination with Keytruda (pembrolizumab) in Advanced or Metastatic Malignancy
The purpose of the study is to look at how your body tolerates LVGN6051, how safe LVGN6051 may be, and how LVGN6051 is taken up ... -
A Phase 1 First-in Human Multi-Center Open Label Dose-Escalation Study to Determine the Safety Tolerability Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors (AbbVie M19-345)
The purpose of the study is to look at safety and efficacy of study drug ABBV-151 alone and in combination with study drug ABBV-181. We ...